Aegis Therapeutics Invited to Participate in Panel Session at 10th Anniversary - Drug Delivery Technologies & Deal-Making Summit.

SAN DIEGO -- Aegis Therapeutics, a leader in intranasal and transmucosal delivery of peptide, protein, and non-protein macromolecular drugs, today announced that Edward T. Maggio, Ph.D., President and Chief Executive Officer, will participate in a panel entitled, "Difficult to Deliver Peptides and Proteins" at the 10th Anniversary Drug Delivery Technologies & Deal-Making Summit taking place in New Brunswick, NJ from September 26th through the 28th, 2005. The panel session will take place on September 27th at the Hyatt Regency New Brunswick - New Brunswick, NJ.

This expert panel, composed of participants from pharmaceutical and biotechnology companies and academia, will discuss important issues and advances relating to delivery of peptide and protein therapeutics

"I am pleased to participate in a panel focused on a subject of such great and current importance to the pharmaceutical and biopharmaceutical industries," stated Edward T. Maggio, Ph.D., President and Chief Executive Officer of Aegis. "Recent industry reports that nearly 700 peptide drugs are currently in clinical and preclinical development, along with rapidly growing interest in 'biogenerics' in the US, EU and Asia, makes this particularly timely."

About Aegis Therapeutics

Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail(TM) drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail(TM) absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail(TM) also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: http://www.aegisthera.com.